Abeona Therapeutics Inc. (NASDAQ:ABEO)’s share price traded up 6.2% on Thursday . The stock traded as high as $4.31 and last traded at $4.31, with a volume of 58,969 shares trading hands. The stock had previously closed at $4.06.

Several equities analysts have recently weighed in on the company. Zacks Investment Research cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 22nd. FBR & Co reiterated a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a report on Friday, August 26th. Maxim Group set a $6.00 price objective on Abeona Therapeutics and gave the company a “buy” rating in a report on Thursday, August 18th. Finally, Rodman & Renshaw reiterated a “buy” rating and set a $17.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, May 18th.

The firm’s market cap is $149.95 million. The firm has a 50-day moving average price of $3.45 and a 200-day moving average price of $2.87.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.06. On average, equities research analysts anticipate that Abeona Therapeutics Inc. will post ($0.71) earnings per share for the current fiscal year.

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.